RUMI Scientific announces Receipt of Two-Year Phase II SBIR Award totaling $1.9 Million to Accelerate Discovery and Development of Novel Therapeutic Candidates for the Treatment of Autism
RUMI Scientific announces Receipt of Two-Year Phase II SBIR Award totaling $1.9 Million to Accelerate Discovery and Development of Novel Therapeutic Candidates for the Treatment of Autism
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- RUMI Scientific, Inc. (“RUMI”) a developer of therapies for rare and neurodegenerative diseases using its high throughput organoid phenotypic screening platform, today announced it has received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Mental Health totaling $1.9 MM.
RUMI’s organoid platform utilizes an unbiased phenotypic approach to target drug discovery for CNS and other diseases. In addition to its lead candidate in preclinical development for Huntington’s disease, Rumi is leveraging its platform to identify potential new therapeutic approaches aimed at treating various genetic forms of autism and peripheral diseases such as chronic kidney disease. The Phase II award will fund RUMI’s ongoing work to model later stages of brain development relevant to developing therapeutics for autism and other neurological disorders.
The grant funding, the first Phase II SBIR award the Company has received since its inception, focuses on the development of an in vitro tool to mimic physiological and pathological neuronal networks of forebrain neurons termed cerebroids. The project brings together an interdisciplinary team to develop an innovative solution that will accelerate the discovery of new therapeutic candidates for autism, which has seen limited innovation despite remaining an area of major unmet medical need. To-date, the Company has received a total of more than $4 million in non-dilutive technology and grant funding.
“This grant funding is an important milestone in the continued evolution of RUMI and will jumpstart our discovery and development efforts in autism,” said Allen Fienberg, PhD, Chief Executive Officer of RUMI. “We are continuing to advance our lead program, an orally-administered BRD9 inhibitorBRD9 inhibitor for Huntington’s Disease, toward clinical development and look forward to expanding our CNS efforts to include work in the autism space as a result of this non-dilutive capital.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.